Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2017—InvMan, an inventory management software solution from Cove Laboratory Software, automates inventory management by providing direct scanning of vendor reagent barcode labels. Using a portable scanner, the vendor 1-D or 2-D barcode is scanned and uploaded to the reagent database in InvMan.
July 2017—BioMérieux announced that BioFire Diagnostics, its molecular biology affiliate, celebrated the opening of its Alain Mérieux Center for Molecular Diagnostics facility in Salt Lake City. The facility, home to more than 1,000 employees, is dedicated to the development of FilmArray, BioFire’s molecular PCR multiplex system for the syndromic diagnosis of infectious diseases.
July 2017—Agena Bioscience introduced targeted research panels for the detection of somatic mutations from lung and colon cancers. The UltraSeek Lung and Colon Panels enable the detection of mutations as low as 0.1 percent minor allele frequency from circulating tumor cells and circulating tumor DNA. The iPlex HS Lung and Colon Panels enable detection of mutations as low as one percent MAF from solid tumor tissue.
July 2017—BloodCenter of Wisconsin launched its VWF GPIbM Activity assay, which aims to more accurately measure von Willebrand factor activity. The assay detects qualitative VWF defects, reducing variability and providing more precise, reliable, and sensitive test results.
July 2017—NanoMolecularDX announced it has acquired the assets of Nuclea Biotechnologies. Assets include all of the intellectual property, biological material, capital equipment, licenses, FDA approvals and allowances, marketing and customer materials, trademarks, and all relevant scientific data. NMDX began selling in May HER2/neu blood testing kits acquired from Nuclea.
July 2017—Eppendorf introduced its Eppendorf Forensic DNA Grade product line, which complies with the requirements of ISO 18385. This standard specifies requirements for the production of products used in the collection, storage, and analysis of biological material for forensic DNA purposes.
July 2017—Enzo Life Sciences unveiled its Multiview Plus (mouse-HRP/rabbit-AP) IHC Kit (brown/green). This nonbiotin nanopolymer detection system contains reagents and materials that detect and localize antigens in formalin-fixed, paraffin-embedded tissues. The kit optimizes the IHC process by including the entire workflow, from antigen retrieval to visualization.
July 2017—MDxHealth SA announced that results from a retrospective study demonstrated that its ConfirmMDx for Prostate Cancer test improved the identification of African American men at risk for aggressive cancer missed by a prostate biopsy. The study findings were presented in a podium session at the 2017 American Urological Association annual meeting in Boston.
July 2017—Roche announced the CE-IVD launch of the Cobas Liat PCR System with four assays, including a 20-minute real-time PCR nucleic acid test to detect Clostridium difficile.
July 2017—Cynvenio Biosystems announced the availability of ClearID Total Insight Breast Cancer, a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient’s biological health is designed to measure immune health status and detect genetic mutations associated with cancer.
